Tag Archives: Sobi

November, 2018

January, 2018

November, 2017

July, 2017

  • 5 July

    FDA Grants Orphan Drug Designation to Sobi’s Treatment for MPS IIIA

    STOCKHOLM–(BUSINESS WIRE)–Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the company’s development candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, a …

March, 2017

March, 2015